Inhibitor Therapeutics Net Tangible Assets

As of the most recent data (June 2026), INTI shows a net tangible assets of $-2.6M. That compares with $720K in the prior-year period — down 457.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INTI's net tangible assets is now $-2.6M (was $720K) — a 457.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Inhibitor Therapeutics is outperforming or lagging.

Tracking INTI's net tangible assets over time shows whether Inhibitor Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-2.6M That compares with $720K in the prior-year period — down 457.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Inhibitor Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $-2.6M) with ownership activity and broader fundamentals.

Inhibitor Therapeutics's net tangible assets is $-2.6M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.